OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET

OptimizeRx Corp. (Nasdaq: OPRX), a prominent provider of healthcare technology solutions, has announced a conference call scheduled for November 6, 2025, at 4:30 p.m. ET. This call is intended to discuss the Company's financial results for the third quarter ending September 30, 2025. A press release detailing those results will be issued prior to the call.

The call will be hosted by OptimizeRx management and will include a question-and-answer session, allowing investors and analysts to engage directly with the leadership team. Participants can join the call via a toll-free number (1-844-825-9789) or an international line (1-412-317-5180), using the conference ID 10203796. For those who prefer online access, a webcast option is available and can be accessed through a specific link provided by the Company.

OptimizeRx, headquartered in Waltham, Massachusetts, leverages advanced technology, including AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT). These innovations enable life sciences companies to effectively engage healthcare professionals (HCPs) and patients, enhancing communication and expediting treatment decisions for improved patient outcomes.

The Company positions itself as a pivotal player in bridging the gap between HCP and direct-to-consumer (DTC) strategies, driving meaningful interactions while prioritizing privacy and patient-centric technology. Following the conference call, a replay will be accessible for 12 months via the Investors section of the OptimizeRx website, ensuring stakeholders can remain informed about the Company's performance and strategic direction.

For inquiries, OptimizeRx encourages contact with Chief Business Officer Andy D'Silva or Investor Relations representative Steven Halper at LifeSci Advisors, LLC.

As OptimizeRx Corp. prepares for its third-quarter earnings call on November 6, 2025, investors should take this opportunity to assess its performance in an increasingly competitive healthcare technology landscape. The company’s strategic focus on bridging the gap between life sciences and healthcare providers through innovative AI-driven solutions, such as the Dynamic Audience Activation Platform (DAAP), positions it well for long-term growth.

Ahead of the earnings call, it is prudent to consider key performance indicators, including revenue growth, user engagement statistics, and overall market adoption of their technologies. Given the anticipated release of the press release, analysts will be scrutinizing quarterly results for indications of whether the company's strategies are translating into tangible financial success. Particularly, investors should watch for metrics regarding the expansion of its user base and any new partnerships that may have been forged.

With the telehealth and digital health markets evolving rapidly, OptimizeRx’s commitment to privacy-safe, patient-centric technology could serve as a significant competitive advantage. The company's ability to demonstrate improved patient outcomes through their targeted solutions will be crucial in establishing credibility with investors and potential clients alike.

Moreover, the question-and-answer portion of the call will be crucial for obtaining insight into management's strategic vision and responses to market challenges. Investors should prepare questions focusing on competitive positioning, technological advancements, and any regulatory challenges that may arise in their operations.

Overall, while OptimizeRx shows promise, it is essential to analyze the forthcoming results carefully. A careful evaluation of their financial performance and an understanding of market dynamics will provide a clearer picture of the company’s potential for future growth. As always, investors should proceed with caution, considering both the risks and opportunities inherent in the healthcare technology sector.